Ingested IFN-α : Results of a pilot study in relapsing-remitting MS

To investigate whether ingested human recombinant interferon-alpha2a (IFN-alpha2a) was safe and whether treatment reduces the number of gadolinium-enhanced lesions on serial MRI in patients with active relapsing-remitting MS (RRMS). Entry criteria included clinically definite RRMS and one or more ga...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2001-09, Vol.57 (5), p.845-852
Hauptverfasser:	BROD, S. A, LINDSEY, J. W, VRIESENDORP, F. S, AHN, C, HENNINGER, E, NARAYANA, P. A, WOLINSKY, J. S
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Analysis of Variance Biological and medical sciences Brain - drug effects Brain - pathology Double-Blind Method Humans Immunologic Factors - administration & dosage Immunomodulators Interferon Type I - administration & dosage Magnetic Resonance Imaging Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Neurology Outcome Assessment (Health Care) Pharmacology. Drug treatments Pilot Projects Recombinant Proteins Tumor Necrosis Factor-alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!